UBS Group Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00

Harmony Biosciences (NASDAQ:HRMY) had its target price dropped by analysts at UBS Group from $46.00 to $36.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price points to a potential upside of 27.47% from the company’s previous close.

Several other equities analysts have also weighed in on the company. Oppenheimer reissued an “outperform” rating and set a $62.00 price objective on shares of Harmony Biosciences in a report on Monday, November 24th. Deutsche Bank Aktiengesellschaft downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Monday. Needham & Company LLC lowered their price target on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday. Zacks Research raised shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $42.67.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock traded up $0.05 during mid-day trading on Wednesday, hitting $28.24. 950,704 shares of the stock were exchanged, compared to its average volume of 947,679. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87. The company has a 50-day simple moving average of $36.57 and a 200 day simple moving average of $34.19. The company has a market capitalization of $1.63 billion, a P/E ratio of 8.91, a P/E/G ratio of 0.25 and a beta of 0.84. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.72 and a current ratio of 3.75.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.46). The company had revenue of $243.78 million for the quarter, compared to the consensus estimate of $240.04 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. Harmony Biosciences’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.85 EPS. Sell-side analysts anticipate that Harmony Biosciences will post 2.43 earnings per share for the current fiscal year.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sandip Kapadia sold 20,961 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $35.92, for a total transaction of $752,919.12. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 50,640 shares of company stock worth $1,932,256 over the last 90 days. Corporate insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Harmony Biosciences

Large investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its stake in shares of Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares in the last quarter. Leonteq Securities AG purchased a new stake in Harmony Biosciences during the fourth quarter valued at about $30,000. Allworth Financial LP grew its stake in shares of Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after buying an additional 602 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Harmony Biosciences by 4,185.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock worth $37,000 after buying an additional 1,130 shares during the period. Finally, Clearstead Advisors LLC boosted its holdings in Harmony Biosciences by 145.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after acquiring an additional 699 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $55 price target (implies large upside), supporting bullish investor sentiment. HC Wainwright Reaffirms Buy, $55 PT
• Positive Sentiment: Needham trimmed its price target to $44 but kept a “buy” rating, which still signals confidence in upside for the company’s growth story. Needham Lowers PT to $44, Keeps Buy
• Positive Sentiment: Harmony reported strong 2025 results (WAKIX revenue +21% YoY) and reiterated FY2026 net revenue guidance of over $1 billion, underpinning the core commercial outlook. Company Press Release — Strong 2025 Results & 2026 Guidance
• Positive Sentiment: Management is targeting $1.0B–$1.04B WAKIX revenue in 2026 and is expanding its late-stage CNS pipeline, which supports longer-term growth expectations. WAKIX 2026 Revenue Target & Pipeline Expansion
• Neutral Sentiment: Earnings call transcript and slide deck are available for investors to assess detail on revenue mix, margins, and guidance assumptions — useful but informational rather than catalytic by itself. Earnings Call Transcript
• Negative Sentiment: Q4 EPS materially missed estimates: $0.38 vs. consensus ~$0.84, despite a revenue beat — raises near-term earnings concerns and explains some downward pressure. Q4 EPS Miss Coverage
• Negative Sentiment: Bank of America cut its price target to $28 and moved to an “underperform” rating, a clear bearish signal that can pressure the stock. BofA Lowers PT to $28, Underperform
• Negative Sentiment: Truist lowered its rating to “hold,” reducing buy-side conviction from another sell-side firm. Truist Lowers to Hold
• Negative Sentiment: Coverage highlighting legal and generic risks around WAKIX is drawing attention to downside scenarios that could affect future revenue and valuation. Article on WAKIX Legal & Generic Risks

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.